INS and type 2 diabetes mellitus: The aim of our study was to evaluate CV risks in patients with T2DM treated with the GLP 1-R agonist exenatide twice daily (EBID) and/or insulin in a large, nationally-representative longitudinal ambulatory-care medical record database.